A new industry body, the British Biosimilars Association (BBA), has been formally launched with the sole focus of increasing the understanding and use of biosimilar medicines in the UK.
The BBA is the expert sector group of the British Generic Manufacturers Association (BGMA) exclusively focused on biosimilar medicines. BBA members’ core focus will be advancing biosimilars to the same extent as those elsewhere in Europe. Currently, the UK lags behind some European countries in the take-up of biosimilar medicines, according to the BBA. Currently, there are seven biosimilar molecules on the market in the UK (somatropin, follitropin alfa, filgrastim, infliximab, epotein alfa, insulin glargine and etanercept
The new association is open to all manufacturers of biosimilar medicines , not just BGMA members, who wish to promote their use in the interests of British patients. The association’s founder members are Accord, Allergan, Boehringer Ingelheim, Napp, Sandoz, and Teva.
Source: British Biosimilars Association